Tiny exosome bubbles get first human safety test
NCT ID NCT07219940
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 40 times
Summary
This early-stage trial tests a new drug called SOB100, which uses tiny particles called exosomes to deliver a targeted therapy. The study involves 15 healthy adults and aims to check if the drug is safe and tolerable. It is a dose-escalation study, meaning participants receive increasing doses to find the safest range.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY SUBJECTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Parexel International - Baltimore Early Phase Clinical Unit
RECRUITINGBaltimore, Maryland, 21225, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SOB100 (HLA-G-targeted exosome)
What this could lead to
If safe, this could pave the way for future studies using exosomes to deliver targeted therapies for diseases like cancer or autoimmune disorders.
What could go wrong
This is a very early Phase 1 trial in only 15 healthy people, focused on safety, not effectiveness. It may not lead to any treatment, and unexpected side effects are possible.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.